Clinical trials
Recurrent or Metastatic Nasopharyngeal Carcinoma clinical trials
Below are recruiting recurrent or metastatic nasopharyngeal carcinoma clinical trials, each written for real people, not researchers. We’re tracking 2,384 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06383520RecruitingEarly Phase 1
PET imaging for GPC3 in liver cancer
This study tests a new PET imaging method that targets GPC3, a protein often found in liver cancer cells. It may help doctors see and understand liver cancer better, especially in people with newly diagnosed or recurrent disease.
Wuhan, HubeiAges 18–65 - NCT06393816RecruitingPhase 2
Durvalumab plus chemotherapy for advanced LCNEC lung cancer
This trial tests a combination of the immunotherapy drug durvalumab (Imfinzi) with standard chemotherapy (etoposide and a platinum drug) as a first treatment for advanced large-cell neuroendocrine carcinoma of the lung. The goal is to see if this combination works better than chemotherapy alone.
Aix-en-ProvenceAges 18 years+ - NCT06394492RecruitingPhase 3
Testing a new drug for platinum-resistant ovarian cancer
This study tests a new drug called SHR-A1921 for people with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if it can shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06395519RecruitingPhase 1/Phase 2
Study of ETX-19477 for advanced solid tumors
This trial tests an experimental drug called ETX-19477 for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective, especially for those with certain genetic changes (BRCA2 mutations).
Phoenix, ArizonaAges 18 years+ - NCT06397235RecruitingPhase 2
Combination therapy for large liver cancer tumors
This trial tests whether a combination of two treatments—chemoembolization (DEB-TACE) plus chemotherapy given through the liver artery (RALOX-HAIC)—works better than chemoembolization alone for people with large liver cancer tumors (over 7 cm). The goal is to see if the combination shrinks tumors more effectively.
Guangzhou, GuangdongAges 18–75 - NCT06404983Recruiting
Opioid-free anesthesia for breast cancer surgery
This study tests whether breast cancer surgery can be done safely without using opioid pain medicines during anesthesia. The goal is to see if avoiding opioids leads to fewer side effects and a smoother recovery.
Ioannina, EpirusAges 18–99 - NCT06406608Recruiting
Personalized drug test for drug-resistant lung cancer
This trial tests a new way to choose your next treatment by growing a mini version of your tumor (an organoid) in a lab and seeing which drugs kill it best. It is for people with drug-resistant non-small cell lung cancer who have already tried at least two standard treatments.
Zhengzhou, HenanAges 18–75 - NCT06406660Recruiting
Organoid-guided drug selection for recurrent small cell lung cancer
This study uses a patient's own tumor cells grown in the lab (called an organoid) to find the most effective drug for recurrent small cell lung cancer. It aims to personalize treatment after standard therapy stops working.
Zhengzhou, HenanAges 18–75 - NCT06408584Recruiting
Short radiation plus two drugs for returning esophageal cancer
This trial tests a short course of radiation combined with two drugs (raltitrexed and tislelizumab) for people with esophageal cancer that has returned after standard treatment. The goal is to see if these combinations can shrink tumors and improve survival.
HefeiAges 18 years+ - NCT06420063RecruitingPhase 1/Phase 2
Two-step CAR-T therapy for AML with CD33/CD123
This study tests a new kind of immunotherapy called CAR-T cells that are engineered to find and attack leukemia cells carrying certain markers (CD33, CD123, or CLL-1). The treatment is given in two steps, aiming to kill cancer cells more effectively and possibly with fewer side effects.
Beijing, Beijing MunicipalityAges 6–90 - NCT06421298RecruitingPhase 2
Tafolecimab and sintilimab plus chemo for advanced lung cancer
This trial is testing a new combination of treatments, including an immune drug (sintilimab) and a cholesterol-lowering drug (tafolecimab), along with chemotherapy, for people with advanced lung cancer that no longer responds to standard immunotherapy.
Beijing, Beijing MunicipalityAges 18–75 - NCT06424522Recruiting
Enema program for bowel problems after rectal cancer surgery
This trial tests a special enema program to help people with ongoing bowel problems (called LARS) after rectal cancer surgery. If standard treatments haven't worked, this program might offer a new way to manage symptoms like urgency and leakage.
Columbus, OhioAges 18 years+ - NCT06429813Recruiting
Remote exercise program for men with metastatic prostate cancer
This trial tests whether a remotely supervised exercise program (walking and stationary cycling) can help men with metastatic prostate cancer who are starting hormone therapy. Participation involves following an exercise plan at home and may help manage side effects.
Charlottesville, VirginiaAges 18 years+ - NCT06430541RecruitingPhase 1
Psilocybin therapy for fear of cancer recurrence
This trial tests if psilocybin-assisted therapy can help reduce the intense worry that cancer might come back. It is for people who have finished their main treatments for early-stage breast cancer or advanced ovarian cancer.
Aurora, ColoradoAges 21 years+ - NCT06434896Recruiting
Blood test to guide chemotherapy in stage II colon cancer
This trial is for people with stage II colon cancer who are not currently getting chemotherapy. It uses a blood test to look for tumor DNA, so doctors can decide if chemotherapy might help prevent the cancer from coming back.
's-HertogenboschAges 18 years+ - NCT06435403Recruiting
COVID-19 Antibody Study in Ethiopian Healthcare Workers
This study looks at how antibodies from a past COVID-19 infection protect healthcare workers in Ethiopia from getting sick again. Participants will give blood samples and report any COVID-19 symptoms.
Addis AbabaAges 18 years+ - NCT06441110RecruitingPhase 3
BCG instillation for medium- to high-risk bladder cancer
This trial tests whether a specific schedule of BCG (a weakened germ that boosts the immune system) placed directly into the bladder is safe and effective for medium- to high-risk bladder cancer that hasn't grown into the muscle. It aims to see if adjusting the standard BCG course can work better for people with a PD-L1-positive tumor.
Fuzhou, FujianAges 18–75 - NCT06444126Recruiting
Study of fever seizures coming back and epilepsy risk
This study follows children who had their first seizure with a fever to see how often seizures come back and if they develop epilepsy. It helps doctors understand which children need extra monitoring.
Ho Chi Minh CityAges 1 month–8 years - NCT06445114RecruitingPhase 2
Blood-Guided Chemoradiation for HPV-Positive Throat Cancer
This study tests whether a blood test that looks for circulating HPV DNA (ctDNA) can help doctors decide if you need chemotherapy after surgery for HPV-positive throat cancer. After you have surgery to remove the cancer, you receive radiation (possibly with chemotherapy) — the results of the blood test guide whether or not to add chemo.
Beverly Hills, CaliforniaAges 18 years+ - NCT06445803RecruitingPhase 1
CAR-T therapy for adults with certain blood cancers
This trial tests a type of immunotherapy called CAR-T cells that target two proteins (CD19 and CD22) on cancer cells. It may be an option for adults with B-cell acute lymphoblastic leukemia (ALL) or B-cell non-Hodgkin lymphoma (NHL) that has come back or not responded to earlier treatments.
Nanchang, JiangxiAges 18 years+ - NCT06455605RecruitingPhase 1
Combination therapy after surgery for recurrent glioblastoma
This trial tests a combination of two drugs (D2C7-IT and 2141-V11) given directly into the brain after surgery for people with recurrent glioblastoma. The goal is to see if this treatment is safe and can help control the tumor.
Durham, North CarolinaAges 18 years+ - NCT06456515Recruiting
Regorafenib, sintilimab, and electroacupuncture for advanced colorectal cancer
This trial tests a combination of two drugs (regorafenib and sintilimab) plus electroacupuncture for people with advanced colorectal cancer that hasn't responded to standard treatments. The goal is to see if this triple therapy can help shrink tumors or slow the cancer's growth.
ChangzhouAges 18–75 - NCT06462495RecruitingEarly Phase 1
Comparing two PSMA PET/CT scans for prostate cancer
This trial compares two types of PET/CT scans (using different radioactive tracers) to see which is better at finding prostate cancer, tracking its return, or spotting spread. It's for people with prostate cancer or those being checked for recurrence after treatment.
Hefei, AnhuiAges 18–90 - NCT06462508RecruitingEarly Phase 1
Comparing two PET scans for prostate cancer detection
This trial compares two types of PET scans—one using a new tracer called [18F]F-PSMA-N5 and another using an existing tracer called [68Ga]Ga-PSMA-11—to see which is better at finding prostate cancer, including early signs of recurrence. If you have or are suspected of having prostate cancer, this study may help determine how advanced the disease is.
Hefei, AnhuiAges 18–90
Hear when a new Recurrent or Metastatic Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic nasopharyngeal carcinoma?
- Yes. Clin2 currently lists 2,384 recruiting recurrent or metastatic nasopharyngeal carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic nasopharyngeal carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic nasopharyngeal carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Recurrent Nasopharyngeal Carcinoma
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Metastatic Nasopharyngeal Carcinoma
- Metastatic Nasopharyngeal Squamous Cell Carcinoma
- Recurrent Nasopharyngeal Squamous Cell Carcinoma
- Nasopharyngeal Carcinoma
- Metastatic Renal Cell Carcinoma
- Nasopharyngeal Carcinoma (NPC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.